Presentation Abstract

Abstract Number: 1358
Presentation Title: Are physician recommendations for BRCA 1/2 testing among breast cancer patients appropriate? A population based study
Presentation Time: Monday, Apr 08, 2013, 1:00 PM - 5:00 PM
Location: Hall A-E, Poster Section 11
Poster Board Number: 05
Author Block: Anne Marie McCarthy, Mirar Bristol Demeter, Tracey Fredricks, Kaijun Liao, Judy A. Shea, Peter Groeneveld, Susan M. Domchek, Katrina Armstrong. University of Pennsylvania, Philadelphia, PA
Abstract Body: Purpose: To evaluate the rates and predictors of physician recommendation for BRCA 1/2 testing in breast cancer patients.
Patients and Methods: Women aged 18-64 diagnosed with invasive breast cancer in 2007 in Pennsylvania completed a survey on family history of cancer, physician treatment recommendations, and BRCA 1/2 testing (N=2258). Based on age at diagnosis and family history, women were categorized as high, moderate, or low risk for BRCA 1/2 mutations. Multivariate logistic regression was used to assess the odds of physician recommendation for BRCA 1/2 testing by risk group, age at diagnosis, demographics, and tumor characteristics.
Results: Nearly 25% of participants were at high risk for carrying a BRCA 1/2 mutation based on age at breast cancer diagnosis and family history of breast and/or ovarian cancer. Physician recommendations for BRCA 1/2 testing were strongly associated with risk of carrying a BRCA 1/2 mutation, with 53% of women at high risk reporting a testing recommendation compared to 9% of women at low risk. In addition, physician recommendations were strongly correlated with use of testing in all risk groups. Among women at high risk of mutation, lack of a recommendation for BRCA 1/2 testing was more common among women who were older, had lower income, and were employed.
Conclusion: Although BRCA 1/2 testing recommendations appear to be appropriately correlated with mutation risk among women with breast cancer, a significant proportion of breast cancer patients who meet criteria for BRCA 1/2 testing may not be receiving recommendations for such testing from their providers.